A_randomized_controlled_trial_of_adjuvant_immunotherapy_(murine_monoclonal_antibody_494/32)_in_resectable_pancreatic_cancer._In_a_prospective_randomized_multicentric_trial,_61_patients_from_six_hospitals_with_resectable_pancreatic_cancer_were_recruited_between_1987_and_1989._All_patients_underwent_a_Whipple_resection._Two_weeks_after_surgery,_the_patients_were_randomized_to_be_given_either_intravenous_(IV)_treatment_with_370_mg_(100_mg_loading_dose,_9_x_30_mg_continuing_within_10_days)_of_monoclonal_antibody_(MoAb)_494/32_(Behringwerke_AG,_Marsburg,_Germany)_or_no_additional_anti-cancer_treatment._This_murine_immunoglobulin_(Ig)_G1_antibody_has_been_shown_to_strongly_bind_to_human_pancreatic_cancer_cells_and_to_induce_an_antibody-dependent_cellular_cytotoxicity_(ADCC)._Both_study_groups_were_well_matched_with_respect_to_age,_sex,_tumor_staging,_and_grading._Six_patients_suffered_from_minor_toxicity_(vomiting_and_abdominal_pain)_after_immunotherapy._Ten_months_after_the_end_of_the_recruitment_period,_65%_and_53%_of_the_patients_in_the_treatment_and_control_groups,_respectively,_had_died._Of_the_living_patients,_60%_and_53%_are_alive_with_recurrent_or_progressive_cancer_disease._Median_survival_time_was_428_days_(range,_248_to_510_days)_and_386_days_(range,_296_to_509_days)_in_the_treatment_and_control_groups,_respectively._The_authors_concluded_that_repeated_IV_treatment_with_the_antibody_494/32_is_not_helpful_in_resectable_pancreatic_cancer._This_study_provides_the_first_controlled_data_on_passive_immunotherapy_in_solid_cancer.